SAN FRANCISCO, April 10, 2017 -- Today Zephyr Health, the leading Insights-as-a-Service company, released a report entitled “Powering the Life Sciences Commercial Engine with Market Access Insights.” Based on results from a survey of 60 industry leaders working in market access, medical affairs, marketing and sales, the report examines the challenges with effective market access data integration between market access and commercial teams, and key opportunities to reengineer the business for the future.
According to this report, all survey respondents recognized the importance of a market access-driven commercial model, and the need to more effectively share data to gain any competitive advantage that a formulary change might offer. In fact, more than 40% of participants cite data integration and sharing as the biggest barrier to collaboration between managed markets and sales and marketing teams. Organizational silos and disparate technology solutions play a significant role in these challenges.
“It’s clear from the survey that the Life Sciences industry still needs solutions for effective pull-through by field sales for market access opportunities created by managed care teams” said Lance Scott, chief executive officer, Zephyr Health. “While pharmaceutical companies have a clear understanding of the power these insights can provide, in terms of commercial success, breaking down silos throughout the organization is essential to data integration of any kind. However, these efforts must be supplemented with technology that disseminates rich and predictive insights across the organization in order to stay ahead of competition.”
The “Powering the Life Sciences Commercial Engine with Market Access Insight” global survey examined the landscape for pharmaceutical companies seeking to bridge the insights gap between market access teams and other commercial functions. For more information, download a copy of the Zephyr Health report.
About Zephyr Health
Zephyr Health helps Life Sciences companies – pharmaceutical, biotech, medical device and diagnostics – engage the right physicians, accounts and institutions using insights from global health data. Zephyr Illuminate™ is a leading Insights-as-a-Service solution that integrates thousands of data sources to create precise and predictive insights. From pre-launch to product maturity, Life Sciences companies can make confident decisions faster with data-driven targeting and deep customer profiles.
Zephyr Health is a privately held company headquartered in San Francisco with offices in London, UK, and Pune, India. Zephyr Health is venture backed by Google Ventures, Kleiner Perkins Caufield & Byers, and Icon Ventures. For more information, please visit: www.zephyrhealth.com.
Media contact for Zephyr Health: [email protected]


Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Instagram Outage Disrupts Thousands of U.S. Users
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 



